Cargando…

New insights into IgG4-related disease: emerging new CD4(+) T-cell subsets

PURPOSE OF REVIEW: New insights into IgG4-related disease (IgG4-RD) have recently been obtained. A better understanding of the mechanisms underlying this disease is important for identification of therapeutic targets, which will lead to the development of specific strategies for treatment. RECENT FI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamekura, Ryuta, Takahashi, Hiroki, Ichimiya, Shingo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2019
Materias:	VASCULITIS SYNDROMES: Edited by Hasan Yazici and Yusuf Yazici
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254779/ https://www.ncbi.nlm.nih.gov/pubmed/30422824 http://dx.doi.org/10.1097/BOR.0000000000000558

Ejemplares similares

The association of Behçet's syndrome with HLA-B51 as understood in 2021
por: Takeno, Mitsuhiro
Publicado: (2022)

Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease
por: Kubo, Satoshi, et al.
Publicado: (2022)

Circulating PD-1(+)CXCR5(−)CD4(+) T cells underlying the immunological mechanisms of IgG4-related disease
por: Kamekura, Ryuta, et al.
Publicado: (2018)

Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry
por: Puéchal, Xavier, et al.
Publicado: (2022)

A Distinct Macrophage Subset Mediating Tissue Destruction and Neovascularization in Giant Cell Arteritis: Implication of the YKL‐40/Interleukin‐13 Receptor α2 Axis
por: van Sleen, Yannick, et al.
Publicado: (2021)

Treatment of polyarteritis nodosa with tocilizumab: a new therapeutic approach?
por: Saunier, Aurélie, et al.
Publicado: (2017)

IgG4-related disease administered dupilumab: case series and review of the literature
por: Kanda, Masatoshi, et al.
Publicado: (2023)

Geo-epidemiology of temporal artery biopsy-positive giant cell arteritis in Australia and New Zealand: is there a seasonal influence?
por: De Smit, Elisabeth, et al.
Publicado: (2017)

Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing
por: Ortiz-Fernández, Lourdes, et al.
Publicado: (2023)

Prevalence and risk factors of osteonecrosis of the femoral head in patients with ANCA-associated vasculitis: a multicentre cohort study
por: Mimura, Norihiro, et al.
Publicado: (2023)

The importance of IgG4 in the predictive model of thyroiditis
por: Pandrc, Milena S, et al.
Publicado: (2015)

Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases
por: Izumi, Keisuke, et al.
Publicado: (2015)

Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review
por: Mackie, Sarah Louise, et al.
Publicado: (2015)

PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis
por: Lester, Susan, et al.
Publicado: (2016)

Balancing on the edge: implications of a UK national audit of the use of BSR-BHPR guidelines for the diagnosis and management of polymyalgia rheumatica
por: Das, Parthajit, et al.
Publicado: (2015)

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis
por: Evans, Jobie, et al.
Publicado: (2016)

Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group
por: Chrysidis, Stavros, et al.
Publicado: (2018)

Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis
por: Heijl, Caroline, et al.
Publicado: (2017)

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
por: Yates, Max, et al.
Publicado: (2017)

Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients
por: Prieto-González, Sergio, et al.
Publicado: (2017)

Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis
por: Lai, Lana Yin Hui, et al.
Publicado: (2018)

Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Study
por: Jayne, David, et al.
Publicado: (2019)

T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach
por: Martinez Valenzuela, Laura, et al.
Publicado: (2019)

Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
por: Merkel, Peter A., et al.
Publicado: (2017)

Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?
por: Goodfellow, Nicola, et al.
Publicado: (2017)

Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study
por: Cutolo, Maurizio, et al.
Publicado: (2017)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

Vascular ultrasound for the diagnosis of giant cell arteritis: a reliability and agreement study based on a standardised training programme
por: Chrysidis, Stavros, et al.
Publicado: (2020)

Probability-based algorithm using ultrasound and additional tests for suspected GCA in a fast-track clinic
por: Sebastian, Alwin, et al.
Publicado: (2020)

Cardiovascular drug treatment, statins and biopsy-confirmed giant cell arteritis: a population-based case–control study
por: Turkiewicz, Aleksandra, et al.
Publicado: (2020)

Development and preliminary validation of the Behçet’s syndrome Overall Damage Index (BODI)
por: Piga, Matteo, et al.
Publicado: (2020)

Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody-associated vasculitis—a meta-analysis
por: Kuzuya, Kentaro, et al.
Publicado: (2020)

Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis
por: Teixeira, Vítor, et al.
Publicado: (2019)

Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis
por: Monti, Sara, et al.
Publicado: (2019)

Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis
por: Águeda, Ana F, et al.
Publicado: (2019)

Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2019)

Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab
por: Stone, John H., et al.
Publicado: (2019)

Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool
por: Sebastian, Alwin, et al.
Publicado: (2020)

ANCA-associated renal vasculitis is associated with rurality but not seasonality or deprivation in a complete national cohort study
por: Aiyegbusi, Oshorenua, et al.
Publicado: (2021)

Long‐Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis
por: Merkel, Peter A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f0vkdtc1suq5oclp4cbif43n2u